UK incentives will attract more like us, says Eisai executive
This article was originally published in Scrip
Measures announced in the UK Budget this week "have vindicated our decision to locate a hub in the UK" and will lead other pharmaceutical companies "to redirect investments to the UK now", Gary Hendler, president and CEO of Japanese pharma group Eisai's EMEA operations, told Scrip.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.